# Illumina, Inc.: Form 10-Q for the period ended Sep 27, 2026

- Company: [Illumina, Inc.](/companies/ilmn.md) (CIK 1110803)
- Form: 10-Q
- Filed: 2026-10-30
- Accepted by EDGAR: Oct 30, 2026, 16:14 ET
- Period: 2026-09-27
- Accession: 0001110803-26-000207
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1110803/000111080326000207/ilmn-20260927.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1110803/000111080326000207/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2026-09-27.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2026-06-29 to 2026-09-27 | $1.13bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2025-12-29 to 2026-09-27 | $3.38bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2026-06-29 to 2026-09-27 | $299.0m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2025-12-29 to 2026-09-27 | $1.06bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2026-06-29 to 2026-09-27 | $830.0m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2025-12-29 to 2026-09-27 | $2.32bn | us-gaap:GrossProfit |
| Research and development | 3 months, 2026-06-29 to 2026-09-27 | $244.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2025-12-29 to 2026-09-27 | $736.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2026-06-29 to 2026-09-27 | $281.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2025-12-29 to 2026-09-27 | $826.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2026-06-29 to 2026-09-27 | $305.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2025-12-29 to 2026-09-27 | $759.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2026-06-29 to 2026-09-27 | $24.0m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months, 2025-12-29 to 2026-09-27 | $71.0m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months, 2026-06-29 to 2026-09-27 | $44.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2025-12-29 to 2026-09-27 | $120.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2026-06-29 to 2026-09-27 | $220.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2025-12-29 to 2026-09-27 | $561.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2026-06-29 to 2026-09-27 | $1.43 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2025-12-29 to 2026-09-27 | $3.65 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2026-06-29 to 2026-09-27 | $1.46 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2025-12-29 to 2026-09-27 | $3.70 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2026-06-29 to 2026-09-27 | 154,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2025-12-29 to 2026-09-27 | 154,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2025-12-29 to 2026-09-27 | $909.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2025-12-29 to 2026-09-27 | $118.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2025-12-29 to 2026-09-27 | $379.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Current assets | at 2026-09-27 | $3.04bn | us-gaap:AssetsCurrent |
| Total assets | at 2026-09-27 | $6.81bn | us-gaap:Assets |
| Current liabilities | at 2026-09-27 | $1.16bn | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2026-09-27 | $3.15bn | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1110803/000111080326000207/ilmn-20260927.htm

Filed Oct 30, 2026.
Source: SEC EDGAR, the filing index for accession 0001110803-26-000207. Last ingested by Listed: Nov 14, 2026, 13:59 ET. No prices; not investment advice.
